Recent

% | $
Quotes you view appear here for quick access.

NPS Pharmaceuticals, Inc. Message Board

dcaf7 36 posts  |  Last Activity: Jul 21, 2016 4:39 PM Member since: Apr 24, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • On May 27, 2016, a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. ("Spectrum"), Allos Therapeutics Inc. (the "Company"), and Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, "Dr. Reddy's"), entered into a settlement agreement to resolve their patent litigation relating to Folotyn (pralatrexate injection). As a result of the settlement, Dr. Reddy's will be permitted to market a generic version of Folotyn in the United States on December 1, 2022 or earlier under certain circumstances.
    The Company's litigation against other generic filers continues.

  • Look at slide 6 "Compensation Program Evolution in 2016"
    One third of company performance will be evaluated based on relative total stockholder return. Is it something new?

  • Reply to

    2016 MAJOR catalysts

    by theanalyst88 Jun 2, 2016 3:23 PM
    dcaf7 dcaf7 Jun 2, 2016 4:51 PM Flag

    SELECT-1 is K-Ras mutant NSCLC trial. ASTRA is thyroid cancer trial. Primary completion date for SELECT-1 is May 2016. Expect results in June or July.

  • Reply to

    2016 MAJOR catalysts

    by theanalyst88 Jun 2, 2016 3:23 PM
    dcaf7 dcaf7 Jun 2, 2016 7:46 PM Flag

    I don't know when AZN will make this data available for public but in 1-2 months they will know the outcome of the study for sure.

  • Array BioPharma (ARRY), Pierre Fabre and Merck KGaA, Darmstadt, Germany, today jointly initiated the BEACON CRC (Binimetinib, Encorafenib And Cetuximab Combined to treat BRAF-mutant Colorectal Cancer) trial, a randomized, global Phase 3 clinical trial designed to assess the safety and efficacy of binimetinib (MEK inhibitor), encorafenib (BRAF inhibitor) and Erbitux (monoclonal antibody) in comparison to Erbitux and irinotecan-based therapy in patients with BRAF-mutant colorectal cancer (BRAFm CRC).

  • Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
    Encouraging results in ONT-380 combination therapy in patients with and without brain metastases
    Activity
    •Median progression-free survival (PFS) was 8.2 months.
    •In 34 patients with measurable disease evaluable per RECIST 1.1, an overall response rate of 47% was achieved. Best responses in patients were:
    •One patient with a complete response and 15 patients with partial responses.
    •14 (41%) with stable disease, and four patients (12%) with progressive disease.

    Brain metastases
    •Many of the patients with brain metastases in the study had long-term control of both brain metastases and systemic disease.
    •Progression-free survival in the 30 patients with brain metastases was similar to patients without brain metastases.
    •There were no patients without brain metastases at baseline who developed new clinically apparent brain metastases while on the study.

  • Reply to

    ONT-380 at ASCO

    by dcaf7 Jun 5, 2016 9:45 AM
    dcaf7 dcaf7 Jun 6, 2016 12:50 PM Flag

    No, I think it is initiation of a new Phase 3 study. Also it could be an expectation of positive updated OS data from NEMO study which will be featured during an oral presentation today at 1:15 p.m. CT.

  • Reply to

    ONT-380 at ASCO

    by dcaf7 Jun 5, 2016 9:45 AM
    dcaf7 dcaf7 Jun 6, 2016 2:32 PM Flag

    No OS benefit in mutant NRas melanoma.

  • Reply to

    mmmm, something weird is going on here !!!!!

    by bigofbig Jun 6, 2016 2:36 PM
    dcaf7 dcaf7 Jun 6, 2016 5:22 PM Flag

    "If CIs overlap, that means no statistical significance." When 95% confidence intervals for the means of two independent populations don’t overlap, there will indeed be a statistically significant difference between the means (at the 0.05 level of significance). However, the opposite is not necessarily true. CI’s may overlap, yet there may be a statistically significant difference between the means.

  • Reply to

    New Name

    by tartiaboy Jun 8, 2016 10:31 AM
    dcaf7 dcaf7 Jun 8, 2016 7:08 PM Flag

    I don't like his statement that they were able to achieve Neulasta effect with 1/2 or 1/3 dose of SPI-2012. Simply not true. Why did he spend a lot of time speaking about Marqibo in the end of presentation as if it was a very important drug for the company? Why not to talk about Beleodaq or Folotyn which is a major source of revenue for the company? Why Evomela market shrunk to $80-100M from $100M and $100-120M?

  • Sandoz OK to sell generic version in late 2022
    Best news in a long time

  • Reply to

    Spectrum and Sandoz settle Folotyn patent suit

    by dcaf7 Jun 9, 2016 7:41 AM
    dcaf7 dcaf7 Jun 9, 2016 7:49 AM Flag

    Now they need to settle with the last generic filer, Fresenius Kabi USA, LLC.

  • Jun 9, 2016
    According to The Fly, in a report released yesterday, Chris Howerton from Jefferies reiterated a Hold rating on Spectrum Pharmaceuticals.
    Howerton wrote, “Our takeways from presentation and breakout session: 1.) ‘2012 appears to be on-track with mgmt focused on the execution of the ongoing pivotal ph 3 trial. (topline data exp 1H18). 2.) ‘Pozi’ is on-track w/ pot’l ph 2 data from partner by YE16. 3.) FDA has asked for a meeting ~1mth before apazi PDUFA (Dec 11) 4.) Marqibo sales volatility are due to small pt population (~1600) Pipeline Update: SPI-2012: All attention is on ‘2012 in breast cancer (exp topline data 1H18), for which we model as a pot’l (prob adjst) $200M sales opportunity. Mgmt appears thoughtful regarding the study design and execution of ‘2012 by offering in- home blood collection. Recall, ‘2012 requires patients to give blood frequently during the study, therefore mgmt believes by choosing 84 sites and offering convenience, enrollment will be fulfilled quickly & efficiently. Apaziquone: Mgmt reiterated their PDUFA date (Dec-11-2016) set by the FDA for apaziquone (Qapzola) in non-muscle invasive bladder cancer. Interestingly, mgmt added that the FDA has asked for a meeting ~1mth before the set date. While we do not currently value apazi in bladder cancer, we recognize that there is a large unmet clinical need and the FDA is eager for an efficacious product to be available. Poziotinib (‘pozi’): During the presentation, pozi was compared to neratinib, a competing pan-HER 2 inhibitor, comparisons included the ORR b/t the two (60% ORR, n=10 in pozi vs 24% ORR n=63 in neratinib).”

  • Reply to

    Jefferies analyst on Spectrum

    by dcaf7 Jun 16, 2016 5:53 PM
    dcaf7 dcaf7 Jun 16, 2016 7:27 PM Flag

    It is ODAC meeting. Nothing new.

  • Reply to

    Jefferies analyst on Spectrum

    by dcaf7 Jun 16, 2016 5:53 PM
    dcaf7 dcaf7 Jun 16, 2016 7:41 PM Flag

    Because they "do not currently value apazi in bladder cancer".

  • Reply to

    Jefferies analyst on Spectrum

    by dcaf7 Jun 16, 2016 5:53 PM
    dcaf7 dcaf7 Jun 17, 2016 11:27 AM Flag

    "This is longer than what Raj has been saying." Summary slide in Jefferies presentation says "SPI-2012 potential NDA filing in 2018". Therefore, topline data in 1H18 sounds reasonable.

  • Reply to

    Jefferies analyst on Spectrum

    by dcaf7 Jun 16, 2016 5:53 PM
    dcaf7 dcaf7 Jun 17, 2016 11:49 AM Flag

    Raj is not good at dates and numbers. And he is not accurate in presenting data. You know that.

  • To estimate revenue from SPI-2012 you may consider the following:
    1. Neulasta brought $4.6B for Amgen in 2014.
    2. Biosimilars rarely take more than 30% of market share from branded drugs in Europe, where they have been commercially available since 2006. It means, all biosimilars of Neulasta could compete for $4.6B x 0.3 = $1.38B
    3. Introduction of a biosimilar leads to a discount of 20% to 30% compared to the branded version. Assuming 25%, total market for biosimilars of Neulasta is $1.04B.
    4. Three companies, Sandoz, Apotex and Coherus are way ahead of Spectrum in bringing Neulasta biosimilars to the market, and Teva, most likely, will be the fourth one. Assuming equal share in sales between five companies, each company could generate $200M.
    5. Spectrum can hardly keep up with the marketing muscle of Teva and Sandoz. Therefore, Spectum’s slice of the pie should be less than $200M.
    Other thoughts?

  • Reply to

    SPI-2012 potential

    by dcaf7 Jun 17, 2016 8:29 PM
    dcaf7 dcaf7 Jun 18, 2016 12:45 PM Flag

    Yes, it was discussed here in length. Last year, in analyst day presentation Jeffrey Vacirca said: “Obtaining superiority is not important”. It is a doctor's opinion who knows the field. I tend to agree with him. This drug will be viewed as biosimilar.

  • Reply to

    SPI-2012 potential

    by dcaf7 Jun 17, 2016 8:29 PM
    dcaf7 dcaf7 Jun 19, 2016 12:50 PM Flag

    Yes, it does. Needs to be adjusted. In 2015, Neulasta sales in U.S. was $ 3.9B.

NPSP
45.970.00(0.00%)Feb 20 3:59 PMEST